Louis Breton, Rampart Bioscience CEO
Rampart Bioscience raises $125M for non-viral gene therapies
A new California biotech startup has launched with plans to develop genetic medicines that are durable, redoseable, and perhaps most importantly, don’t overwhelm health budgets …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.